Navigation Links
New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
Date:5/20/2009

NIH Should Fix Standards to Allow Use of Current Stem Cell Lines

SANTA MONICA, Calif., May 20 /PRNewswire-USNewswire/ -- -- Regulations governing stem cell research proposed by the Obama Administration -- unless modified before final implementation on July 1 -- prohibit federal funding of important research that had received funding under the Bush Administration, Consumer Watchdog said today. The nonpartisan, nonprofit group called on the National Institutes of Health to change the draft regulations.

On March 9, President Obama signed an executive order intended to lift restrictions on federal funding of human embryonic stem cell research. As part of the order, the National Institutes of Health (NIH) were directed to develop regulations "to help ensure that NIH-funded research in this area is ethically responsible, scientifically worthy, and conducted in accordance with applicable law."

"Most of us were heartened when President Obama lifted Bush Administration restrictions on funding stem cell research, but the perverse effect of these proposed NIH rules is that the limited research scientists were able to conduct under Bush will now be ineligible for federal funding," said John M. Simpson, Consumer Watchdog's Stem Cell Project Director. "Certainly this is not what President Obama intended and the regulations must be modified."

Bush allowed the NIH to fund research on embryonic stem cell lines that were derived before 9 pm, Aug. 9, 2001. In practice there were about 20 lines that were available to scientists that qualified for federal money. Embryonic stem cells, which have the potential to develop into virtually any cell in the body, are derived from embryos left over from in vitro fertilization (IVF) treatments and would otherwise be destroyed.

The Bush approved stem cell lines were derived before the proposed NIH rules and do not meet some o
'/>"/>

SOURCE Consumer Watchdog
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. State, Federal Officials Remind Health Care Workers, Other at-Risk Individuals to Get Annual Flu Shot
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
4. Test for Life Commends North Carolina Rules Commission for Implementing CDC Recommendations for HIV Testing
5. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
6. A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
7. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
8. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
9. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
10. Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases
11. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 1Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 4